Advertisement
Key findings of the preclinical trial -- in which either a TengionNeo-Bladder Augment or a biodegradable mesh scaffold alone was surgicallyimplanted following partial, trigone-sparing cystectomy and both groups wereevaluated clinically at one, three, six and nine months -- show that theTengion Neo-Bladder Augment restored baseline urodynamics as early as sixmonths after implantation and led to a structurally and functionally completeregenerated bladder wall as early as nine months. In contrast, scaffoldimplants alone failed to return to urodynamic baseline by the studytermination and failed to regenerate a complete bladder wall.
Advertisement
"We continue to see great promise in our neo-bladder research programs andthese latest data underscore the potential of Tengion's Autologous OrganRegeneration Platform(TM) to provide a neo-organ that allows the body toregenerate a functional organ," said Dr. Bertram, Senior Vice President,Science and Technology of Tengion. "We are looking forward to formally sharingthese findings with our peers and continuing to develop our Neo-BladderAugment and the Tengion Neo-Bladder Replacement(R) to meet the criticalpatient needs that exist today."
About Tengion
Tengion, a clinical stage biotechnology company, focuses on developing,manufacturing and commercializing human neo-organs and neo-tissues using ourAutologous Organ Regeneration Platform(TM). Tengion uses biocompatiblematerials and a patient's own (autologous) cells to create neo-organs orneo-tissues that are designed to catalyze the body's innate ability toregenerate. Tengion's product candidates may ultimately address the mostcritical problems facing organ and tissue failure patients, enabling people tolead healthier lives without donor transplants or the side effects of relatedtherapies. For more information on the company and current clinical trials,visit Tengion online at: http://www.tengion.com.
SOURCE Tengion, Inc.
